Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.intimp.2020.107022 http://scihub22266oqcxt.onion/10.1016/j.intimp.2020.107022 33160854!7500882!33160854     free     free     free Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 233.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 267.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+Immunopharmacol 2021 ; 90 (ä): 107022 Nephropedia Template TP {{tp|p=33160854|t=2021. Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy |pdf=|usr=}}{{33160854}} gab.com Text Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy JO: Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33160854 #FOAvip Gender influences clinical presentations, duration and severity of symptoms, and therapy outcome in coronavirus disease 2019 (COVID-19) infection. Whether the immune response to Talpha1 treatment for SARS-CoV-2 differs between the sexes, and whether this difference explains the male susceptibility to COVID-19, is unclear. This study aimed to investigate the efficiency and safety of Talpha1 treatment and provide a basis for practically identifying gender differences characteristics and features of COVID-19. One hundred twenty-seven patients had COVID-19 symptoms and tested COVID19-positive (female 42.52%) in Wuhan union hospital were enrolled for medication. They were randomly divided into groups Control and Talpha1 intervention. Seventy-eight patients received a subcutaneous injection of 1.6 mg Talpha1, based on supportive treatment for 15 days. The control group included untreated 49 COVID19 patients closely matched for gender and age and received regular supportive treatment. In this retrospective analysis, we found that COVID-19-infected males reported more symptoms than COVID-19-infected females. A high degree of gender differences-related variability was observed in CRP and PCT levels and the cell counts of many lymphocyte subpopulations in the COVID-19 patients after Talpha1 intervention. Levels of CRP and IL-6 were higher in Talpha1-treated male group than Talpha1-treated female group, while the level of PCT was significantly lower in Talpha1-treated male group. Gender differences may be a factor in sustaining COVID-19 immunity responded to Talpha1, male and female show statistically significant differences in relevance to cytokine production associated with the development of a more significant number of symptoms. This leaves the question of identifying gender-specific risk factors to explain these differences. Twit Text FOAVip Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy ????Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33160854 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33160854 #FOAvip English Wikipedia <ref>{{Cite pmid|33160854}}</ref> Gender-associated difference following COVID-19 virus infection: Implications for thymosin alpha-1 therapy #MMPMID33160854 Li X; Liu L; Yang Y; Yang X; Wang C; Li Y; Ge Y; Shi Y; Lv P; Zhou H; Luo P; Huang S Int Immunopharmacol 2021[Jan]; 90 (ä): 107022 PMID33160854show ga Gender influences clinical presentations, duration and severity of symptoms, and therapy outcome in coronavirus disease 2019 (COVID-19) infection. Whether the immune response to Talpha1 treatment for SARS-CoV-2 differs between the sexes, and whether this difference explains the male susceptibility to COVID-19, is unclear. This study aimed to investigate the efficiency and safety of Talpha1 treatment and provide a basis for practically identifying gender differences characteristics and features of COVID-19. One hundred twenty-seven patients had COVID-19 symptoms and tested COVID19-positive (female 42.52%) in Wuhan union hospital were enrolled for medication. They were randomly divided into groups Control and Talpha1 intervention. Seventy-eight patients received a subcutaneous injection of 1.6 mg Talpha1, based on supportive treatment for 15 days. The control group included untreated 49 COVID19 patients closely matched for gender and age and received regular supportive treatment. In this retrospective analysis, we found that COVID-19-infected males reported more symptoms than COVID-19-infected females. A high degree of gender differences-related variability was observed in CRP and PCT levels and the cell counts of many lymphocyte subpopulations in the COVID-19 patients after Talpha1 intervention. Levels of CRP and IL-6 were higher in Talpha1-treated male group than Talpha1-treated female group, while the level of PCT was significantly lower in Talpha1-treated male group. Gender differences may be a factor in sustaining COVID-19 immunity responded to Talpha1, male and female show statistically significant differences in relevance to cytokine production associated with the development of a more significant number of symptoms. This leaves the question of identifying gender-specific risk factors to explain these differences. |*Age Factors[MESH] |*Sex Factors[MESH] |Adjuvants, Immunologic/*therapeutic use[MESH] |Aged[MESH] |C-Reactive Protein/metabolism[MESH] |COVID-19 Drug Treatment[MESH] |COVID-19/*epidemiology[MESH] |China/epidemiology[MESH] |Female[MESH] |Humans[MESH] |Interleukin-6/metabolism[MESH] |Lymphocyte Subsets/*pathology[MESH] |Male[MESH] |Middle Aged[MESH] |Retrospective Studies[MESH] |SARS-CoV-2/*physiology[MESH]Gender-associated difference following COVID-19 virus infection: Impli(epmc).pdf DeepDyve Pubget Overpricing